IntelliPharmaCeutics International (TSE:IPCI.H) has released an update.
Intellipharmaceutics International, a pharmaceutical company known for its controlled-release drug delivery technology, is facing a downgrade from the OTCQB market to the OTC Expert Market due to non-filing of its annual financial statements. This move restricts public access to the company’s stock quotes, limiting visibility to broker-dealers and sophisticated investors. The company is also under a cease trade order by the Ontario Securities Commission for the same filing delinquency, with no clear assurance of rectifying the filing issues.
For further insights into TSE:IPCI.H stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
